Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.
No analysis yet
No analysis yet
JNJ delivered solid FY2025: $94.2B revenue (+6.0% reported, +4.2% adj. operational), adj. EPS $10.79. DARZALEX (~15% of revenue) is the engine. STELARA biosimilar erosion is live and accelerating. Int...